Open-label, single-arm, multiple-dose safety, titration, and pharmacokinetic study of AFREZZA® in pediatric subjects ages 4 to 17 years with type 1 diabetes mellitus
Linda DiMeglio, MD
Primary Investigator
Overview
The purpose of this research study is to measure how much of the study drug (Afrezza) gets into your blood
after a single dose and measure how well it works to control your blood sugar level. We also want to make sure
this study drug is safe for children and adolescents between 4 and 17 years old.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
type 1 diabetes mellitus
-
Age: Between 4 Years - 12 Years
-
Gender: All
Inclusion Criteria
Diagnosed with Type 1 diabetes for at least 1 year
Currently on multiple daily injections
No history of asthma
Connect with a study center near you
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact